Osteoporosis is a disease where low bone mineral density and microstructure deterioration lead to low bone strength and high risk of fracture. Because metabolic disorders will accelerate bone loss and renal failure，which can increase the risk of osteoporosis that will lead to fracture or even death. Denosumab is a receptor activator of nuclear factor⁃κB ligand inhibitor that is widely used in the treatment of osteoporosis. In recent years， there are increasing applications of denosumab in hemodialysis patients with osteoporosis. This paper reviews the application and research progress of denosumab in the treatment of osteoporosis in hemodialysis patients